California News Reporter

“PARP Inhibitors Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the  PARP Inhibitors Market. 

The PARP Inhibitors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

PARP Inhibitors Pipeline Analysis

The report provides insights into: 

• The report provides detailed insights into the emerging PARP inhibitors in the Market and the aggregate therapies developed by major pharma companies.

• It accesses the different PARP Inhibitors therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development.

• It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the PARP Inhibitors Market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Route of Administration

PARP Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Infusion

• Intradermal

• Intramuscular

• Intranasal

• Intravaginal

• Oral

• Parenteral

• Subcutaneous

• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Vaccines

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

Learn How the Ongoing Clinical & Commercial Activities will Affect the PARP Inhibitors Therapeutic Segment @ 

https://www.delveinsight.com/sample-request/parp-inhibitors-pipeline-insight

PARP Inhibitors Therapeutics Landscape

There are approx. 30+ key companies developing PARP Inhibitors. Currently, BeiGene is leading the therapeutics market with its PARP Inhibitors drug candidates in the most advanced stage of clinical development.

The Key Players in the PARP Inhibitors Therapeutics Market Include:

• TESARO

• AstraZeneca

• Sun BioPharma

• Eisai Co

• BeiGene

• IMPACT Therapeutics

• Ribon Therapeutics

And Many Others

Key Products Covered in the Report Include:

• Niraparib  

• Olaparib

• SBP 101

• 2X 121

• SBP 101: Panbela Therapeutics

• Pamiparib: BeiGene

• OX 401: Onxeo

• Veliparib: Abbvie

• Rucaparib: Clovis Oncology

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @ 

https://www.delveinsight.com/sample-request/parp-inhibitors-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. PARP Inhibitors Current Treatment Patterns

4. PARP Inhibitors – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. PARP Inhibitors Late Stage Products (Phase-III)

7. PARP Inhibitors Mid-Stage Products (Phase-II)

8. PARP Inhibitors Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. PARP Inhibitors Discontinued Products

13. PARP Inhibitors Product Profiles

14. Key Companies in the PARP Inhibitors Market

15. Key Products in the PARP Inhibitors Therapeutics Segment

16. Dormant and Discontinued Products

17. PARP Inhibitors Unmet Needs

18. PARP Inhibitors Future Perspectives

19. PARP Inhibitors Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @ 

https://www.delveinsight.com/sample-request/parp-inhibitors-pipeline-insight

Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic healthcare market today @ Healthcare Partner Identification Solutions

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/